A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus

Stopped Study terminated early as a result of the outcome of the pre-planned Interim Analysis

Conditions

• Lupus Erythematosus, Systemic

Interventions

• DRUG: Placebo
• DRUG: Ustekinumab (approximately 6 mg/kg)
• DRUG: Ustekinumab 90 mg

Sponsor

Janssen Research & Development, LLC